Protocols and Concepts

Listed below are Moffitt CCOP Research Base studies. Click on the study title to view the protocol/concept status and eligibility requirements.

Active Protocols:

• HLMCC 0402 Oral Glutamic Acid to Decrease Vincristine Toxicity in Children with Cancer (07/30/09)
  
  
• HLMCC 0501 Stress Management Therapy for Patients Undergoing Chemotherapy (07/30/09)
  
  
• HLMCC 0502 Thyroid Function & Breast Cancer: A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed with Breast Cancer and the Magnitude of Change in Thyroid Function Post-Chemotherapy (07/30/09)
  
  
• HLMCC 0802 An Open Label Randomized Phase II of an Appetite Stimulant, Cyproheptadine Hydrochloride, With and Without a Nutritional Supplement, in Children with Cancer/Treatment-Related Weight Loss (07/30/09)

Pending Protocols:

• HLMCC 0703 Prevention of Cancer/Treatment-Related Weight Loss in Children Receiving Moderate to Highly Emetic Chemotherapy  (01/22/09)
  
  
• HLMCC 0806 A randomized, placebo controlled phase II study of lisinopril and CoReg (carvedilol phosphate extended-release) to reduce trastuzumab (Herceptin) -induced cardiotoxicity in patients with breast cancer scheduled to receive trastuzumab (07/30/09)
  
  
• HLMCC 0803 A Randomized, Phase II Placebo-Controlled Study of the Use of Extended-Release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy (07/30/09)
  
  

Concepts:

• HLMCC 0709 Risperidone for the Treatment of Cerebellar Mutism Syndrome: A Randomized, Phase II, Double-Blind, Placebo-Controlled Study (02/04/08)